解锁希望：抗血管内皮生长因子受体抑制剂及其在胶质母细胞瘤治疗中的潜力。

Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment.

机构信息

Hematology-Oncology Department, Hôtel-Dieu de France University Hospital, Saint Joseph University of Beirut, Beirut, Lebanon.

出版信息

Crit Rev Oncol Hematol. 2024 Jun;198:104365. doi: 10.1016/j.critrevonc.2024.104365. Epub 2024 Apr 25.

DOI:10.1016/j.critrevonc.2024.104365

PMID:38677355

Abstract

PURPOSE

This systematic review summarizes evidence of VEGFR gene mutations and VEGF/VEGFR protein expression in glioblastoma multiforme (GBM) patients, alongside the efficacy and safety of anti-VEGFR tyrosine kinase inhibitors (TKIs) for GBM treatment.

METHODS

A comprehensive literature review was conducted using PubMed up to August 2023. Boolean operators and MeSH term "glioma," along with specific VEGFR-related keywords, were utilized following thorough examination of existing literature.

RESULTS

VEGFR correlates with glioma grade and GBM progression, presenting a viable therapeutic target. Regorafenib and axitinib show promise among studied TKIs. Other multi-targeted TKIs (MTKI) and combination therapies exhibit potential, albeit limited by blood-brain barrier penetration and toxicity. Combining treatments like radiotherapy and enhancing BBB penetration may benefit patients. Further research is warranted in patient quality of life and biomarker-guided selection.

CONCLUSION

While certain therapies hold promise for GBM, future research should prioritize personalized medicine and innovative strategies for improved treatment outcomes.

摘要

目的

本系统综述总结了血管内皮生长因子受体（VEGFR）基因突变和血管内皮生长因子/血管内皮生长因子受体（VEGF/VEGFR）蛋白表达在胶质母细胞瘤（GBM）患者中的证据，以及抗血管内皮生长因子受体酪氨酸激酶抑制剂（TKI）治疗 GBM 的疗效和安全性。

方法

使用 PubMed 进行了全面的文献检索，检索时间截至 2023 年 8 月。在仔细检查现有文献的基础上，使用了布尔运算符和 MeSH 术语“glioma”，以及特定的 VEGFR 相关关键字。

结果

VEGFR 与胶质瘤分级和 GBM 进展相关，是一个有前途的治疗靶点。研究中的 TKI 中，regorafenib 和 axitinib 显示出潜力。其他多靶点 TKI（MTKI）和联合治疗也有一定的潜力，但受到血脑屏障穿透性和毒性的限制。联合治疗如放疗和增强血脑屏障穿透性可能使患者受益。需要进一步研究患者的生活质量和基于生物标志物的选择。